Outcomes

As a result of participating in this activity, learners will be better able to:

Explain related procedures in a way that patients can understand
Treat SI joint pain

Accreditation & Designation

Release date: This activity was released 8/20/2022.

Termination date: The content of this activity remains eligible for CME Credit until 8/19/2025, unless reviewed or amended prior to this date.

Claiming Credit: Watch the entire presentation and complete the Improvement Plan/Evaluation.

Neurovations Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Neurovations Education designates this other activity (blended learning) for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity includes discussions of unlabeled or investigational uses of commercial and/or developmental products.

This activity includes discussions and explorations of new and evolving topics. Such inclusion includes adequate justifications of statements based upon current science, evidence and clinical reasoning.

Disclosure of Financial Relationships & Measures to Resolve of Conflicts of Interest

[Presenter] Zachary McCormick discloses the following financial relationships within the past 24 months: Research: Avanos Medical, Boston Scientific, Relievant Medsystems, SPR Therapeutics; Consulting: FUSmobile, Saol Therapeutics, SI Bone, Stryker

No other person with control of, or responsibility for, the planning, delivery, or evaluation of accredited continuing education has, or has had within the past 24 months, financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships have been mitigated. Materials were reviewed in advance of the activity by person(s) that do not have conflicts of interest related to the content. In some cases, content may have been modified as part of the review and mitigation process. All clinical recommendations are evidence-based and free of commercial bias (e.g., peer-reviewed literature, adhering to evidence-based practice guidelines).

Additional Reading

Burnham, T., Sampson, J., Speckman, R. A., Conger, A., Cushman, D. M., & McCormick, Z. L. (2020). The effectiveness of platelet-rich plasma injection for the treatment of suspected sacroiliac joint complex pain; a systematic review. Pain Medicine, 21(10), 2518-2528.
Chu CR, Rodeo S, Bhutani N, Goodrich LR, Huard J, Irrgang J, LaPrade RF, Lattermann C, Lu Y, Mandelbaum B, Mao J, McIntyre L, Mishra A, Muschler GF, Piuzzi NS, Potter H, Spindler K, Tokish JM, Tuan R, Zaslav K MW. Optimizing Clinical Use of Biologics in Orthopaedic Surgery: Consensus Recommendations From the 2018 AAOS/NIH U-13 Conference.; 2018.
Navani A, Gupta D. Role of intra-articular platelet-rich plasma in sacroiliac joint pain. Tech Reg Anesth Pain Manag 2015;19(1–2):54–9.
Ko GD, Mindra S, Lawson GE, Whitmore S, Arseneau L. Case series of ultrasound-guided platelet-rich plasma injections for sacroiliac joint dysfunction. J Back Musculoskelet Rehabil 2017; 30(2):363–70.
Singla, V., Batra, Y. K., Bharti, N., Goni, V. G., & Marwaha, N. (2017). Steroid vs. platelet‐rich plasma in ultrasound‐guided sacroiliac joint injection for chronic low back pain. Pain Practice, 17(6), 782-791.
Elksniņš-Finogejevs, A., Vidal, L., & Peredistijs, A. (2020). Intra-articular platelet-rich plasma vs corticosteroids in the treatment of moderate knee osteoarthritis: a single-center prospective randomized controlled study with a 1-year follow up. Journal of Orthopaedic Surgery and Research, 15(1), 1-10.